Right goal, wrong strategy: Why Trump’s ‘Made in America’ plan leaves us vulnerable

A generic drug finished in an American factory but dependent on a single overseas supplier for its active ingredient may be less secure than an imported medicine produced at two independent plants with multiple qualified suppliers. That distinction matters as President Donald Trump moves to bring generic-drug manufacturing back to the United States. He has […]

Read it at Washington Examiner ↗

← Front page